Locoregional Recurrence of Squamous Cell Carcinoma of the Head and Neck (HNSCC) research hub

A Phase 3 Multicenter, Randomized, Open-label Study of ASP-1929 Photoimmunotherapy in Combination With Pembrolizumab Versus Standard of Care in the First-line Treatment of Patients With Locoregional Recurrence of Squamous Cell Carcinoma of the Head and Neck (HNSCC) With No Distant Metastases

This study looks at a new treatment called ASP-1929 Photoimmunotherapy combined with Pembrolizumab for head and neck cancer that has come back in the same area. It's compared to standard treatments to see which works better at helping people live longer.